The company will inform the members of the US Congress regarding the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) for the treatment of high-risk individuals with COVID-19.
The post Japan’s Takeda begins development of plasma-derived therapy for COVID-19 appeared first on Pharmaceutical Business review.